NCT02600104Unknown不适用
Clinical Study to Evaluate the Performance of the PicoWayTM Picosecond Fractional Laser for Wrinkles Reduction
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 74
- 试验地点
- 7
- 主要终点
- Efficacy of PicoWay for facial wrinkles reduction treatment assessed by blinded evaluators based on Fitzpatrick Classification and Degree of Elastosis.
研究概览
简要总结
Prospective clinical study, Up to 100 healthy adult volunteers seeking Treatment of Wrinkles Reduction in the facial area, males or females of 18 to 75 years of age, from up to 5 investigational sites.
详细描述
This is an open-label, multi-center study. Subjects in this study will receive up to four (4) facial treatments in 3-8 weeks interval, with the PicoWayTM device-fractional hand piece 1064nm and/or 532nm according to the study protocol. Subjects will be followed by phone 7 days post first treatment by study staff, and will return for follow-up (FU) visits at the clinic at: 6 weeks and 12 weeks following the last treatment.
Methodology described in the protocol to evaluate efficacy and safety of treatments will be carried out at each visit at the clinic.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy female and male subjects between 18 to 75 years of age
- •Has Fitzpatrick skin type I-VI
- •Subjects seeking treatment for wrinkles reduction and willing to undergo laser treatments for improvement
- •Have mild to moderate bilateral perioral and/or periorbital wrinkles
- •Willing to receive the proposed PicoWayTM fractional treatments and comply with all study (protocol) requirements
- •Willing to have photographs and images taken of the treated areas to be used in evaluations, publications and presentations (subject identity will be masked)
- •For female subjects: not pregnant or lactating and is either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide or abstinence)
- •Informed consent process is completed and subject consent is signed
排除标准
- •Pregnant or planning to become pregnant, having given birth less than 3 months ago, and/or breast feeding
- •Hypersensitivity to light exposure
- •Active sun tan in facial area
- •Suffering from significant skin conditions in the treated areas or inflammatory skin conditions, including, but not limited to, open lacerations or abrasions, hidradenitis, or dermatitis of the treatment area prior to treatment (duration of resolution as per the Investigator's discretion) or during the treatment course
- •Is taking medication(s) for which sunlight is a contraindication
- •Has a history of squamous cell carcinoma or melanoma
- •History of keloid scarring, abnormal wound healing and / or prone to bruising
- •History of epidermal or dermal disorders (particularly if involving collagen or microvascularity), including collagen vascular disease or vasculitic disorders
- •Has used oral isotretinoin (Accutane®) within 12 months of initial treatment or plans on using during the course of the study. Note: Skin must regain its normal degree of moisture prior to treatment, e.g., lack of noticeable skin flaking, skin peeling and skin surface roughness.
- •A laser procedure, a peel or has used lightening creams that was performed in the area to be treated with the past six months
- •History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications
- •Known allergy to lidocaine, tetracaine, Xylocaine or epinephrine
- •Subjects with pigmented lesions that are considered not acceptable by the study investigator or any condition that, in the investigator's opinion, would make it unsafe to treat.
- •As per the investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study
结局指标
主要结局
Efficacy of PicoWay for facial wrinkles reduction treatment assessed by blinded evaluators based on Fitzpatrick Classification and Degree of Elastosis.
时间窗: day 0 up to 9 months
assessed by blinded evaluators.
次要结局
- Safety of PicoWay treatment by Adverse events record during all study(day 0 up to 9 months)
- Evaluate investigator satisfaction assessed by questionnaire(from 24 weeks up to 36 weeks)
- Evaluate subject satisfaction assessed by questionnaire(from 24 weeks up to 36 weeks)
- Improvement in Fitzpatrick Classification and Degree of Elastosis, as assessed by study investigator(from 3 weeks up to 9 months)
研究者
研究点 (7)
Loading locations...
相似试验
已完成
不适用
Safety and Efficacy of Single Therapy Versus Double and Triple Therapy of the Pellevé™ Wrinkle Treatment System for the Treatment of Moderate Facial WrinklesAppearance of Facial WrinklesNCT01299103Ellman International40
已完成
不适用
A Study to Evaluate Effectiveness and Safety of Hyaluronic Acid (HA) FillersVolume Deficiency of the MidfaceNCT03869450Galderma R&D90
已完成
Unknown
A study to assess the effect of palonosetron in preventing propofol paiASA 1 and ASA 2 patientsJPRN-UMIN000050665Bangalore Medical College and Research Institute100
已完成
不适用
Clinical trial on the efficacy on the wrinkle conforming to the guideline of Japanese Cosmetic Science SocietyHealthy volunteerJPRN-UMIN000035286ikoderm Research Inc.76
已完成
不适用
Clinical trial on the efficacy on the wrinkle conforming to the guideline of Japanese Cosmetic Science SocietyHealthy volunteerJPRN-UMIN000038406ikoderm Research Inc.80